Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

University of Washington, Seattle, WA 98109, USA.
The Lancet Oncology (Impact Factor: 24.69). 03/2012; 13(5):459-65. DOI: 10.1016/S1470-2045(12)70090-6
Source: PubMed


Brain metastases commonly develop in patients with melanoma and are a frequent cause of death of patients with this disease. Ipilimumab improves survival in patients with advanced melanoma. We aimed to investigate the safety and activity of this drug specifically in patients with brain metastases.
Between July 31, 2008, and June 3, 2009, we enrolled patients with melanoma and brain metastases from ten US centres who were older than 16 years into two parallel cohorts. Patients in cohort A were neurologically asymptomatic and were not receiving corticosteroid treatment at study entry; those in cohort B were symptomatic and on a stable dose of corticosteroids. Patients were to receive four doses of 10 mg/kg intravenous ipilimumab, one every 3 weeks. Individuals who were clinically stable at week 24 were eligible to receive 10 mg/kg intravenous ipilimumab every 12 weeks. The primary endpoint was the proportion of patients with disease control, defined as complete response, partial response, or stable disease after 12 weeks, assessed with modified WHO criteria. Analyses of safety and efficacy included all treated patients. This trial is registered with, number NCT00623766.
We enrolled 72 patients: 51 into cohort A and 21 into cohort B. After 12 weeks, nine patients in cohort A exhibited disease control (18%, 95% CI 8-31), as did one patient in cohort B (5%, 0·1-24). When the brain alone was assessed, 12 patients in cohort A (24%, 13-38) and two in cohort B (10%, 1-30) achieved disease control. We noted disease control outside of the brain in 14 patients (27%, 16-42) in cohort A and in one individual (5%, 0·1-24) in cohort B. The most common grade 3 adverse events in cohort A were diarrhoea (six patients [12%]) and fatigue (six [12%]); in cohort B, they were dehydration (two individuals [10%]), hyperglycaemia (two [10%]), and increased concentrations of serum aspartate aminotransferase (two [10%]). One patient in each cohort had grade 4 confusion. The most common grade 3 immune-related adverse events were diarrhoea (six patients [12%]) and rash (one [2%]) in cohort A, and rash (one individual [5%]) and increased concentrations of serum aspartate aminotransferase (two [10%]) in cohort B. One patient in cohort A died of drug-related complications of immune-related colitis.
Ipilimumab has activity in some patients with advanced melanoma and brain metastases, particularly when metastases are small and asymptomatic. The drug has no unexpected toxic effects in this population.
Bristol-Myers Squibb.

1 Follower
33 Reads
  • Source
    • "If there is a response to Ipi treatment at all, some of them are long-term responses. Ipi was also found to be effective in patients with brain metastases, especially in the subgroup of non-symptomatic (small) metastases.41 The presence of antibodies to NY-ESO-1, an antigen expressed in advanced melanoma, and a rise in absolute lymphocyte count in the blood, increase the likelihood of a response to Ipi.42 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Whereas thin melanomas have an excellent prognosis after sufficient surgical treatment, melanoma disease in advanced stages is still a therapeutic challenge. After decades of frustrating studies, new therapeutic strategies have come up in the past few years. On the one hand, increasing insights into the molecular aberrations in melanoma have led to specific "targeted" therapies to affect only the mutated tumor cells, as in many other types of cancers. Today there are few "targeted" substances which are already approved and successfully used for single or combination therapy, but many others are under development. While on the other hand, nonpersonalized strategy substances have been developed successfully inducing an immunologic tumor response. Both kinds of therapy have been found to result in an improvement not only of the response rate, but also of the overall survival in metastatic disease, which represents a milestone in melanoma therapy. However, using these therapies there is still much to learn regarding the effects, the side effects, and the limitations of these promising substances.
    Full-text · Article · Sep 2014 · Cancer Management and Research
  • Source
    • "This colitis is thought to be secondary, due to dysregulation of the gastrointestinal mucosal immunity, leading to alterations in the enteric flora and infiltration of inflammatory cells in the gastrointestinal mucosa.30 Ipilimumab is also associated with grade 3 fatigue and an increase in serum aspartate transaminase.27 Although the incidence of autoimmune hypophysitis is low (1.8%), this can lead to life-threatening adrenal insufficiency if not recognized early.31 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant melanoma is on the rise. There have been recent advances in targeted agents and immunotherapies that have improved the management and treatment of patients with advanced melanoma. This review discusses the clinical efficacy and unique side effects of targeted immunotherapy and the role of predictive biomarkers in better selection of patients who would derive most benefit from specific treatments. Additionally, this review addresses concerns about the best sequencing algorithms for the currently available targeted agents. By thoroughly and extensively researching through PubMed and the American Society of Clinical Oncology, 69 published articles and abstracts were identified as addressing topics related to malignant melanoma and immunotherapy. The research was divided into subcategories discussing cytokine-based therapy, immunotherapy, molecularly targeted agents, other novel targeted agents, and combination regimens for malignant melanoma. New immune checkpoint inhibitors and targeted agents are able to improve immune-mediated regulatory effects against tumors and, specifically in advanced melanoma, are associated with improvement in overall survival. These new agents have distinct side effects that are often controlled and reversed with dose reductions and/or use of corticosteroids. Currently, there are clinical trials underway to assess the role of combination therapy, whereas other trials are focusing on devising algorithms to delineate how best to sequentially administer these drugs. Although there has been tremendous progress in the management of advanced melanoma with immunotherapy and targeted agents, there is still much to be learned about clinically useful predictive biomarkers and combination therapies as well as how to administer these agents safely.
    Full-text · Article · Jun 2014 · Cancer Management and Research
  • Source
    • "37 Fotemustine + RT 10 8 15 Margolin et al. [42] 31 Temozolomide + RT 9 8 24 Atkins et al. [43] 39 Temozolomide + RT + Talidomide 7.6 7 16 Margolin et al. [50] 51 Ipilimumab 16 10.7 28 Queirolo et al. [51] 146 Ipilimumab 11 11.2 17.2 Falchook et al. [54] 10 Dabrafenib 90 16.8 32 Dummer et al. [56] "
    [Show abstract] [Hide abstract]
    ABSTRACT: The frequency of metastatic brain tumors has increased over recent years; the primary tumors most involved are breast cancer, lung cancer, melanoma and renal cell carcinoma. While radiation therapy and surgery remain the mainstay treatment in selected patients, new molecular drugs have been developed for brain metastases. Studies so far report interesting results. This review focuses on systemic cytotoxic drugs and, in particular, on new targeted therapies and their clinically relevant activities in brain metastases from solid tumors in adults.
    Full-text · Article · May 2014 · Cancer Treatment Reviews
Show more